Advertisement
Device Sectors
Subscribe to Device Sectors
View Sample

FREE Email Newsletter

Zofran (ondansetron): Drug Safety Communication - Risk of Abnormal Heart Rhythms

September 15, 2011 11:30 am | by U.S. Food & Drug Administration | News | Comments

Avoid use of ondansetron in patients with congenital long QT syndrome, and monitor those with electrolyte abnormalities, CHF, bradyarrhythmias, or those taking concomitant medications that prolong the QT interval.

Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales

September 15, 2011 9:40 am | by Bio-Medicine.Org | News | Comments

BOSTON, Sept. 15, 2011 /- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has shown a 32% increase in Breast Endoscopy sales for the period of June through August 2011 as compared to the prior year.  Management recently reported an increase in demand for...

HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A.

September 15, 2011 9:39 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J., Sept. 15, 2011 /- Fidia Farmaceutici S.p.A. (Fidia) announced today that commercial rights for HYALGAN ® (sodium hyaluronate), an injectable treatment for knee pain caused by osteoarthritis when simple painkillers or exercise and physical therapy are not enough,...

Advertisement

Hopkins Study Clears Spinal X-Ray of Wrongdoing

September 15, 2011 9:38 am | by Diagnostic Imaging | News | Comments

Johns Hopkins researchers reviewing a decade of patient records of those who underwent spinal angiography found the procedure to be safe and effective, they report online this week in the journal Neurology.

Targeting Cholesterol May Help Slow Glioblastoma

September 15, 2011 9:33 am | by AACR | News | Comments

Tweet •    These lethal brain cancers depend on cholesterol for growth.•    Laboratory findings identified a tumor survival pathway.•    Glioblastoma is one of the most untreatable cancers. PHILADELPHIA — Glioblastoma is...

Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference

September 15, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Sept. 15, 2011 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that the company will participate in the Sixth Annual JMP Securities Healthcare Conference, being held in New York, New York, September 27 - 28, 2011.  The Alexza corporate...

Q & A: Maximizing Profits in Hospital-Based Radiology Practices, Part 1(3)

September 15, 2011 12:39 am | by Diagnostic Imaging | News | Comments

In the first of a four-part series, Medical Management Professionals Inc.'s Jana Landreth discusses effective metrics for measuring practice revenue and the single biggest cause for lost revenue.

Temperature Monitoring Device From Digitron Helps Pork Farms Take a Big Bite of the Food Market

September 15, 2011 12:36 am | by Bio-Medicine.Org | News | Comments

TORQUAY, England, September 15, 2011 /- When you're producing 1.8 million baked goods each week product quality and food safety is crucial for brand confidence and sustained business growth. A Nottingham-based company which specialises in pork pies and other popular savouries and...

Advertisement

Licensing Agreement for Pharmaceutical Disposal Technology Between Teikoku Pharma USA, Inc. and Verde Environmental Technologies Inc.

September 14, 2011 9:38 pm | by Bio-Medicine.Org | News | Comments

SAN JOSE, Calif., Sept. 14, 2011 /- Teikoku Pharma USA, Inc., ("TPU") is pleased to announce an exclusive license agreement with Verde Environmental Technologies Inc. ("Verde"), a company aimed at developing environmentally responsible solutions for pharmaceutical disposal.  Verde is...

Poll of the Week: Do You Use Voice Recognition Software?

September 14, 2011 3:41 pm | by Diagnostic Imaging | News | Comments

Voice regnition software continues to gain popularity in healthcare as the technology improves. But among radiologists, it's often met with mixed reviews. What do you think?

First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution

September 14, 2011 10:37 am | by Bio-Medicine.Org | News | Comments

BRISBANE, Calif., Sept. 14, 2011 /- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.   (Logo:...

Lupin Announces Launch of Generic KEPPRA XR® Tablets

September 14, 2011 10:34 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, Sept. 14, 2011 /- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of UCB's KEPPRA XR tablets.  Commercial...

Innovative Companies to Present at AdvaMed 2011: The Medtech Conference in Washington, D.C.

September 14, 2011 10:33 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Sept. 14, 2011 /PRNewswire-USNewswire/ -- Medical technology manufacturers from across the United States and around the globe will present their technologies at AdvaMed 2011: The Medtech Conference.  More than 60 innovative device and diagnostic companies and academic...

Advertisement

Portrait Plasma Skin Regeneration Resurfaces at Prestigious Symposium

September 14, 2011 8:40 am | by Bio-Medicine.Org | News | Comments

NYACK, N.Y. and SWANSEA, Wales, Sept. 14, 2011 /- At the historic Grove Park Inn in Asheville, North Carolina, Portrait Plasma Skin Regeneration returned as a technology discussed at the advanced symposium, Controversies & Conversations in Laser and Cosmetic Surgery, directed by Drs....

Thorne Research Launches Thorne Bariatric, an Innovative Nutritional Product Line for Bariatric Surgery Patients

September 14, 2011 8:39 am | by Bio-Medicine.Org | News | Comments

DOVER, Idaho, Sept. 14, 2011 /- Thorne Research, Inc., a leading dietary supplement manufacturer specializing in providing science-based, pure, hypoallergenic nutritional supplements, announced today that it is launching a novel line of dietary supplements – Thorne Bariatric –...

Depuy Spine Announces Global Launch of First Minimally Invasive System for 3D Spine Correction

September 14, 2011 8:39 am | News | Comments

Award-Winning VIPER 3D MIS Correction Set Designed to Treat Complex Pathologies

Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City

September 14, 2011 6:37 am | by Bio-Medicine.Org | News | Comments

BASKING RIDGE, N.J., Sept. 14, 2011 /- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the Annual UBS...

Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting

September 14, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Sept. 14, 2011 /- Delcath Systems, Inc. (NASDAQ: DCTH ) today announced that the Company sponsored an industry symposium at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Munich, Germany—the largest international forum for minimally...

Boston Scientific Names Michael F. Mahoney as Company President, Announces CEO Transition Plan

September 13, 2011 9:37 pm | by Bio-Medicine.Org | News | Comments

NATICK, Mass., Sept. 13, 2011 /- Attracting one of med-tech's most inspiring leaders, Boston Scientific Corporation (NYSE: BSX ) has named Michael Mahoney, 46, as President of the Company, effective October 17, 2011.  Mahoney, Worldwide Chairman of the Medical Device and...

ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results

September 13, 2011 2:38 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Sept. 13, 2011 /- RESMED INC. (NYSE: RMD ), announced today that on Monday, October 24, 2011, it will release its results for the first quarter of fiscal year 2012, ended September 30, 2011. A press release with ResMed's results will be issued after 1:00 p.m. Pacific Time and...

MRI Study Confirms Altered Brain Blood Flow in Gulf War Veterans

September 13, 2011 2:38 pm | by Diagnostic Imaging | News | Comments

Blood flow abnormalities in the brains of veterans with Gulf War illness have persisted 20 years and in some cases have gotten worse, according to a new arterial spin labeled (ASL) MRI study published online in the journal Radiology.

Baxter and the Alpha1 Center Test 100,000th Patient for Alpha-1 Antitrypsin Deficiency (AATD)

September 13, 2011 1:33 pm | by Baxter | News | Comments

Since 2004, Baxter Healthcare Corporation and the Alpha1 Center, a medical diagnostic laboratory in Salt Lake City specializing in the detection of alpha-1 antitrypsin deficiency (AATD), have coordinated a nationwide effort to help physicians rule out the genetic disorder. In August 20

American Pharmacists Association Partners with HHS, CDC and CMS in the Million Hearts Initiative

September 13, 2011 12:33 pm | by Bio-Medicine.Org | News | Comments

WASHINGTON, Sept. 13, 2011 /PRNewswire-USNewswire/ -- The American Pharmacists Association (APhA) announced it has joined the newly launched Million Hearts Initiative, a coordinated approach to preventing cardiovascular disease and stroke in the U.S. Co-led by the U.S. Department of...

Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference

September 13, 2011 9:36 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Sept. 13, 2011 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the UBS Global Life Sciences Conference in New York.   The live presentation takes...

Edison Pharmaceuticals, Inc. Closes Financing

September 13, 2011 9:35 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Sept. 13, 2011 /- Edison Pharmaceuticals, Inc. announced today that it has closed a Series E Preferred Financing. Capital raised will fund US and European approval trials for the company's clinical candidates, EPI-A0001 and EPI-743. Terms of the financing were not...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading